• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lanadelumab may be an effective prophylactic treatment for hereditary angioedema

byJason Nam, MD,Daniel Fisherand1 others
December 12, 2018
in Chronic Disease, Emergency, Genetics, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, prophylactic lanadelumab reduced attack frequency and severity in patients with hereditary angioedema compared to placebo.

2. The most common adverse reactions associated with lanadelumab treatment were injection site reactions and headache.

Evidence Rating Level: 1 (Excellent)   

Study Rundown: Hereditary angioedema is an autosomal dominant disorder caused by C1 inhibitory deficiency (type I) or dysfunction (type II). While current therapeutic options require frequent monitoring or intravenous access, subcutaneous injections of the human monoclonal antibody against kallikrein, lanadelumab, may be used prophylactically to reduce the frequency and intensity of attacks. In this randomized controlled trial, angioedema attack frequency and severity was reduced with lanadelumab compared with placebo over 26 weeks. Quality of life scores were also improved with lanadelumab. The most common adverse effects with lanadelumab treatment were injection site reactions and headaches.

While the use of lanadelumab for patients with hereditary angioedema is promising, the small size of the study introduced imbalances in the demographics that may represent potential confounders. In addition, the study period of only a half-year will require future follow-up to determine long-term efficacy and adverse effects.

Click to read the study in JAMA

Relevant Reading: Inhibiting plasma kallikrein for hereditary angioedema prophylaxis

RELATED REPORTS

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

In-Depth [randomized controlled trial]: In the Hereditary Angioedema Long-term Prophylaxis (HELP) trial conducted at 41 sites in Canada, Europe, Jordan, and the United States, patients who were 12 years or older with a confirmed diagnosis of hereditary angioedema types I or II were recruited to receive lanadelumab (n = 84) or placebo (n = 41). There was a 4-week run-in-period, preceded by a >= 2-week washout of any long-term prophylactic therapy, to determine baseline attack rate. Patients were randomized 2:1 to receive subcutaneously injected lanadelumab or placebo. Lanadelumab patients were assigned in a 1:1:1 ratio: 150mg every 4 weeks, 300mg every 4 weeks, or 300mg every 2 weeks. The primary endpoint was the number of attacks during the 26-week treatment period. The mean number of attacks in the placebo group was 1.97 (CI95 1.64-2.36) compared with 0.48 (CI95 0.31-0.73) in the 150mg every-4-week group, 0.53 (CI95 0.36-0.77) in the 300mg every-4-week group, and 0.26 (CI95 0.14-0.46) in the 300mg every-2-week group. Patients treated with lanadelumab had improved quality of life total scores (150-mg every-4-week group p = .047; 300-mg every-4-week group p = .07; 300-mg every-2-week group p = .001). Patients who received lanadelumab had more attack-free days (p < 0.001), reduced on-demand C1-inhibitor use (20.2% vs 65.9%; p < 0.001), and fewer moderate or severe attacks per month (p < 0.001). Most treatment-related adverse effects were mild to moderate (98.5%) and mainly comprised injection site pain (41.7%), injection site erythema (9.5%), injection site bruising (6.0%), and headache (7.1%).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemalanadelumab
Previous Post

Pediatric palliative care outcome measures often miss quality of life

Next Post

Quick Take:Effect of Cerebellar Stimulation on Gait and Balance Recovery in Patients With Hemiparetic Stroke: A Randomized Clinical Trial

RelatedReports

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema
StudyGraphics

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

April 13, 2022
Cardiology

Donidalorsen reduces attacks in patients with C1 inhibitor deficiency

March 22, 2022
Chronic Disease

Garadacimab significantly reduces frequency of hereditary angioedema exacerbations

March 16, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Infectious Disease

Development and validation of PEN-FAST clinical prediction tool for possible penicillin allergy

March 19, 2020
Next Post
Stroke associated with acute and persistent cognitive decline

Quick Take:Effect of Cerebellar Stimulation on Gait and Balance Recovery in Patients With Hemiparetic Stroke: A Randomized Clinical Trial

Eczema more prevalent among older adults than previously thought

Eczema more prevalent among older adults than previously thought

Isolated mild/moderate thrombocytopenia may not require intervention

Child maltreatment interventions not shown to prevent abuse and neglect

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.